The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
CURE spoke with Dr. Kathie-Ann Joseph about developments in breast most cancers care and the significance of customized, multidisciplinary remedies.Joseph was lately...
Iovance Biotherapeutics introduced information demonstrating that sufferers with superior melanoma skilled excessive response charges when handled with business Amtagvi (lifileucel) in a...
